Two human dendritic cell (DC) subpopulations are recognized: myeloid (MDC) and plasmacytoid (PDC), which mediate distinct immunologic functions. Malignant ascites contained a striking accumulation of PDC, whereas MDC were entirely absent. Tumor draining lymph nodes (LN) contained both PDC and MDC although with marked phenotypic and functional differences compared to blood DC. Little regarding PDC mediated immunity is known. CD4+CD25+ regulatory T cells (Tregs) are elevated in human cancers where they inhibit TAA-specific immunity and predict poor survival. We recently demonstrated a role for PDC in immunopathogenesis of ovarian cancer, including induction of Tregs. We hypothesize that tumor PDC-induced Tregs inhibit tumor-associated antigen (TAA)-specific immunity and facilitate tumor growth, thus contributing to cancer immunopathogenesis. Tumor PDC express high-level B7-H1 that induces T cell IL-10. We will test the hypothesis that tumor PDC B7-H1 is a molecular mechanism for Treg differentiation. Factors inducing Treg differentiation are poorly understood. Understanding these processes is central to unraveling the immunopathologic basis of cancer and developing novel immune-based therapies.
Our specific aims are:
AIM 1 : Test the hypothesis that tumor PDC-activated T cells block TAA-specific immunity. We will use well-characterized in vitro models for human immunity to test effects of naive T cell priming and on defined TAA-specific effector cell functions including cytokine secretion, proliferation, and cytolytic activity. We have preliminarily identified a PDC-activated CD8+ Treg which will be further studied.
AIM 2 : Test the hypothesis that PDC-activated T cells block immune-mediated tumor rejection in vivo. We developed novel chimeric SCID/NOD mouse models for these studies in which autologous human tumor, effector cells and Treg can be studied in vivo. This model allows testing of Treg function, TAA-specific immune suppression and tumor growth in vivo in an autologous setting. Mechanisms will be tested by blocking IL-10, CTLA-4 or other Treg effector arms in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA105207-05
Application #
7618200
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Howcroft, Thomas K
Project Start
2005-07-27
Project End
2010-04-30
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
5
Fiscal Year
2009
Total Cost
$273,408
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Drerup, Justin M; Liu, Yang; Padron, Alvaro S et al. (2015) Immunotherapy for ovarian cancer. Curr Treat Options Oncol 16:317
Hurez, Vincent; Daniel, Benjamin J; Sun, Lishi et al. (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 72:2089-99
Curiel, Tyler J (2012) Immunotherapy: a useful strategy to help combat multidrug resistance. Drug Resist Updat 15:106-13
Lin, Pei-Yi; Sun, Lishi; Thibodeaux, Suzanne R et al. (2010) B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 185:2747-53
Barnett, Brian G; Ruter, Jens; Kryczek, Ilona et al. (2008) Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 622:255-60
Curiel, Tyler J (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 20:241-6
Litzinger, Mary T; Fernando, Romaine; Curiel, Tyler J et al. (2007) IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 110:3192-201
Curiel, Tyler J (2007) Tregs and rethinking cancer immunotherapy. J Clin Invest 117:1167-74
Barnett, Brian; Kryczek, Ilona; Cheng, Pui et al. (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54:369-77